The amount of HE-based pathological damage decreased in WT mice administered PA before I/R but not in anti-IL-33- or anti-ST2-treated WT or IL-33−/− mice administered PA (Figures 3D, E). The gene discussed is IL33; the disease is hereditary elliptocytosis.